Literature DB >> 34767747

MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

Ayaka Sugiura1, Gabriela Andrejeva1, Kelsey Voss1, Darren R Heintzman1, Xincheng Xu2, Matthew Z Madden1, Xiang Ye1, Katherine L Beier1, Nowrin U Chowdhury3, Melissa M Wolf3, Arissa C Young1, Dalton L Greenwood1, Allison E Sewell1, Shailesh K Shahi4, Samantha N Freedman4, Alanna M Cameron5, Patrik Foerch5, Tim Bourne5, Juan C Garcia-Canaveras2, John Karijolich1, Dawn C Newcomb3, Ashutosh K Mangalam4, Joshua D Rabinowitz2, Jeffrey C Rathmell6.   

Abstract

Antigenic stimulation promotes T cell metabolic reprogramming to meet increased biosynthetic, bioenergetic, and signaling demands. We show that the one-carbon (1C) metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regulates de novo purine synthesis and signaling in activated T cells to promote proliferation and inflammatory cytokine production. In pathogenic T helper-17 (Th17) cells, MTHFD2 prevented aberrant upregulation of the transcription factor FoxP3 along with inappropriate gain of suppressive capacity. MTHFD2 deficiency also promoted regulatory T (Treg) cell differentiation. Mechanistically, MTHFD2 inhibition led to depletion of purine pools, accumulation of purine biosynthetic intermediates, and decreased nutrient sensor mTORC1 signaling. MTHFD2 was also critical to regulate DNA and histone methylation in Th17 cells. Importantly, MTHFD2 deficiency reduced disease severity in multiple in vivo inflammatory disease models. MTHFD2 is thus a metabolic checkpoint to integrate purine metabolism with pathogenic effector cell signaling and is a potential therapeutic target within 1C metabolism pathways.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; CRISPR screen; MTHFD2; T cell differentiation; inflammation; mTORC1; metabolic checkpoint; methylation; one carbon metabolism; purine metabolism

Mesh:

Substances:

Year:  2021        PMID: 34767747      PMCID: PMC8755618          DOI: 10.1016/j.immuni.2021.10.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  52 in total

1.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

Authors:  S FARBER; L K DIAMOND
Journal:  N Engl J Med       Date:  1948-06-03       Impact factor: 91.245

2.  The Innate Immune Protein S100A9 Protects from T-Helper Cell Type 2-mediated Allergic Airway Inflammation.

Authors:  Lauren D Palmer; K Nichole Maloney; Kelli L Boyd; A Kasia Goleniewska; Shinji Toki; C Noel Maxwell; Walter J Chazin; R Stokes Peebles; Dawn C Newcomb; Eric P Skaar
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

3.  A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.

Authors:  Grace R Anderson; Peter S Winter; Kevin H Lin; Daniel P Nussbaum; Merve Cakir; Elizabeth M Stein; Ryan S Soderquist; Lorin Crawford; Jim C Leeds; Rachel Newcomb; Priya Stepp; Catherine Yip; Suzanne E Wardell; Jennifer P Tingley; Moiez Ali; Mengmeng Xu; Meagan Ryan; Shannon J McCall; Autumn J McRee; Christopher M Counter; Channing J Der; Kris C Wood
Journal:  Cell Rep       Date:  2017-07-25       Impact factor: 9.423

Review 4.  Methotrexate and its mechanisms of action in inflammatory arthritis.

Authors:  Bruce N Cronstein; Thomas M Aune
Journal:  Nat Rev Rheumatol       Date:  2020-02-17       Impact factor: 20.543

Review 5.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Authors:  Philip M Brown; Arthur G Pratt; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2016-10-27       Impact factor: 20.543

6.  Human mitochondrial MTHFD2 is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase.

Authors:  Minhye Shin; Jessica Momb; Dean R Appling
Journal:  Cancer Metab       Date:  2017-12-06

7.  Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.

Authors:  Huai-Qiang Ju; Yun-Xin Lu; Dong-Liang Chen; Zhi-Xiang Zuo; Ze-Xian Liu; Qi-Nian Wu; Hai-Yu Mo; Zi-Xian Wang; De-Shen Wang; Heng-Ying Pu; Zhao-Lei Zeng; Bo Li; Dan Xie; Peng Huang; Mien-Chie Hung; Paul J Chiao; Rui-Hua Xu
Journal:  J Natl Cancer Inst       Date:  2019-06-01       Impact factor: 13.506

8.  The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion.

Authors:  Vilma Dembitz; Barbara Tomic; Ivan Kodvanj; Julian A Simon; Antonio Bedalov; Dora Visnjic
Journal:  J Biol Chem       Date:  2019-08-20       Impact factor: 5.157

9.  Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.

Authors:  Xingyou Wan; Chao Wang; Zhenyu Huang; Dejian Zhou; Sheng Xiang; Qian Qi; Xinyuan Chen; Eyal Arbely; Chen-Ying Liu; Peng Du; Wei Yu
Journal:  Cell Death Dis       Date:  2020-08-06       Impact factor: 8.469

Review 10.  More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?

Authors:  Zhiyuan Zhu; Gilberto Ka Kit Leung
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

View more
  6 in total

Review 1.  Metabolic adaptation of lymphocytes in immunity and disease.

Authors:  Nicole M Chapman; Hongbo Chi
Journal:  Immunity       Date:  2022-01-11       Impact factor: 31.745

2.  In vivo CRISPR screens reveal a HIF-1α-mTOR-network regulates T follicular helper versus Th1 cells.

Authors:  Bonnie Huang; James D Phelan; Silvia Preite; Julio Gomez-Rodriguez; Kristoffer H Johansen; Hirofumi Shibata; Arthur L Shaffer; Qin Xu; Brendan Jeffrey; Martha Kirby; Stacie Anderson; Yandan Yang; Selamawit Gossa; Dorian B McGavern; Louis M Staudt; Pamela L Schwartzberg
Journal:  Nat Commun       Date:  2022-02-10       Impact factor: 14.919

3.  Increased Development of Th1, Th17, and Th1.17 Cells Under T1 Polarizing Conditions in Juvenile Idiopathic Arthritis.

Authors:  Anna E Patrick; Kayla Shoaff; Tashawna Esmond; David M Patrick; David K Flaherty; T Brent Graham; Philip S Crooke; Susan Thompson; Thomas M Aune
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

4.  Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma.

Authors:  Yuchan Li; Omar Elakad; Sha Yao; Alexander von Hammerstein-Equord; Marc Hinterthaner; Bernhard C Danner; Carmelo Ferrai; Philipp Ströbel; Stefan Küffer; Hanibal Bohnenberger
Journal:  Metabolites       Date:  2022-07-15

5.  A Cluster of Metabolic-Related Genes Serve as Potential Prognostic Biomarkers for Renal Cell Carcinoma.

Authors:  Shuo Huang; Qihan Luo; Junhao Huang; Jiale Wei; Sichen Wang; Chunlan Hong; Ping Qiu; Changyu Li
Journal:  Front Genet       Date:  2022-07-07       Impact factor: 4.772

6.  Deacetylation of MTHFD2 by SIRT4 senses stress signal to inhibit cancer cell growth by remodeling folate metabolism.

Authors:  Fan Zhang; Di Wang; Jintao Li; Ying Su; Suling Liu; Qun-Ying Lei; Miao Yin
Journal:  J Mol Cell Biol       Date:  2022-07-29       Impact factor: 8.185

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.